Benchmark International Logo Blog Mergers and Acquisitions

Archives

Pharma companies set for another big year for M&A

Political and economic uncertainty caused pharma M&A to slacken off in 2016, seeing deal values in the sector falling to $273.7bn from $392.4bn the previous year. While 2016 was far from catastrophic for pharma M&A it failed to reach the all-time highs achieved from the mega-deals in 2015, and the collapse of the $160bn mega-deal between Pfizer and Allergan was just one of the year’s setbacks for the sector.

READ MORE >>

Why The Appetite For M&A In Healthcare Stays Strong

Think healthcare M&A is on its way out in 2016? Think again.

READ MORE >>

M&A Activity Hits an All Time High

The corporate industry world has borne witness to some of the mega deals being signed throughout the year. Pharmaceutical giant Pfizer announced as $160 billion merger with Allergan. A deal that was, according to Bloomberg, “the largest ever deal in the history of healthcare industry and second biggest deal overall on record”.

READ MORE >>
1

Subscribe to Email Updates

Recent Posts

Follow Us on Twitter